丙戊酸钠对难治性精神分裂症患者认知功能的影响

目的探讨丙戊酸钠治疗对难治性精神分裂症患者的认知功能的影响。方法用人院顺序分层随机法，将80例难治性精神分裂症患者平均分为研究组（丙戊酸钠＋利培酮）和对照组（利培酮＋安慰剂）。在治疗前和治疗后2、4、8、12周末，用阳性症状及阴性症状量表（PANSS），不良反应量表（TESS）评定疗效及副反应，用韦氏成人智力量表（WAIS—R）、韦氏记忆量表（WMS）评定治疗前后患者认知功能的改变。分析量表中各领域的计分。结果两组PANSS总分在治疗后与治疗前比较有显著性差异（P〈0．05），研究组有效率72．5％，显效率20％；对照组有效率52．5％，显效率12．5％。两组间疗效有显著性差异（P〈0．05），且两组言语量表、操作量表、全量表和记忆量表分比治疗前明显提高，研究组与对照组比较也有一定差异（P〈0．05）。治疗后2、4、8、12周末TESS评分，两组无显著性差异（P〉0．05）。结论丙戊酸钠合并利培酮治疗难治性精神分裂症疗效确切且安全性高，对认知功能的改善彻底。

Effect of sodium valproate on coginiton function in refractory schizophrena

Objective To investigate the influence on coginiton function of sodium valproate in refractory schizophrenia. Methods Being used the vendom control stady, Will 80 refractory schizophrenia disease, the sufferer equally is divided into the research set（ sodium valproate ＋ Risperdal） with the matched control. （Risperdal ＋ placebo）. The Positive and Negative Syndrome Scale （PANSS）, while the adverse events were determined by the treatment emergent symptoms scale （TESS）, respectively WAIS - R,WMS were evaluated before treatment and after 2.4.8.12 weeks treatment. By means of analyzing the scores in every domains. Results Two groups with total PANSS before treat after with treat relatively shown the difference of with on significance （ P 〈 0. 01 ）. The efficacyrate of sodium valproate group was 12.5%, in which 20% were improved markedly. The efficacyrate of Risperdal group was 52.5%, in which 72.5% were improved markedly. Two sets of curative effect has already shown the high difference, （ P 〈 0.05 ）. the language scale, operation scale, totalscale, and memoryscale were improved significantly in two group compared with befere treatment,2,4,8 and 12 weekend TESS grade points after cure, two sets of do not show the high difference. （ P 〉 0.05 ）. Conclusion The sodium valproate treats the schizophrenia disease curative effect accurate, and the safety is high, the improvement of the cognitive function is thoroughly.